- Policy
- Chong Kun Dang applied for combination of Januvia+Forxiga
- by Lee, Tak-Sun Jan 10, 2022 11:40am
- A combination of diabetes treatments Januvia (Sitagliptin) and Forxiga (Dapagliflozin) is gaining popularity among domestic pharmaceutical companies. Although it can only be released after September next year due to patent rights issues, many domestic pharmaceutical companies are developing products. According to the pharmaceutical industry o
- Company
- Keytruda's reimbursment to be deliberated at DREC meeting
- by Eo, Yun-Ho Jan 10, 2022 05:56am
- The immuno-oncology drug ‘Keytruda’ is finally on its next step to reimbursement after passing Cancer Disease Deliberation Committee's review. According to industry sources, reimbursement expansion of MSD Korea’s PD-1 inhibitor Keytruda (pembrolizumab) will be deliberated by the National Health Insurance Service’s Drug Reimbursement E
- Policy
- Will companies be able to apply for EUA for COVID-19 tx?
- by Lee, Tak-Sun Jan 10, 2022 05:55am
- The development of COVID-19 treatments is actively progressing at home and abroad. Pfizer's oral treatment Paxlovid received EUA from the MFDS in December last year and is expected to be used in Korea soon. Currently, pharmaceutical companies that develop COVID-19 treatments are in a position to introduce them quickly in Korea through EUA lik
- Policy
- Remdesivir has been officially granted over the age of 12
- by Lee, Tak-Sun Jan 10, 2022 05:55am
- The MFDS has approved the change to use Remdesivir, which was first approved as a treatment for COVID-19, only for those aged 12 or older. However, the EUA was decided for this age group to prevent gaps in pediatric treatment under the age of 12. This is the same as when the U.S. FDA officially approved Remdesivir in October 2020. The MFDS
- Policy
- PAGs request expedited new drug listing system to candidates
- by Kim, Jung-Ju Jan 10, 2022 05:55am
- With the presidential election two months ahead, patient groups have asked the presidential candidates to introduce an expedited listing system in the National Health Insurance for new drugs directly related to life. On the 7th, the Korea Alliance of Patients' Organizations had set out to propose and deliver ‘4 key patient policies’ fo
- Company
- Heads of 4 MNCs were newly appointed last year… increase of
- by Eo, Yun-Ho Jan 7, 2022 06:06am
- Four multinational pharmaceutical companies have appointed new CEOs over the past year. According to Dailypharm’s update of CEOs in 32 major multinational pharmaceutical companies, including the Korean Research-based Pharmaceutical Industry Association, heads of 4 pharmaceutical companies were replaced or newly appointed last year. Mo
- Policy
- Dong-A ST applied for Forxiga's Prodrug license
- by Lee, Tak-Sun Jan 7, 2022 06:06am
- It was found that Dong-A ST applied for permission to the MFDS for Forxiga (Dapagliflozin Propanediol Hydrate, AZ), which has been devoted to development. Dong-A ST succeeded in avoiding material patents (scheduled to expire on April 7, 2023) through prodrug for Forxiga, so there is a possibility that it will dominate the generic market when
- Policy
- An additional purchase contract of pfizer tx has been signed
- by Kim, Jung-Ju Jan 7, 2022 06:06am
- The government said it has signed an additional purchase contract for oral treatments (Paxlovid) with Pfizer Korea. According to the KDCA, a total of 1,004,000 oral treatments were pre-purchased through the contract, including 762,000 with Pfizer and 242,000 with MSD Korea. Pfizer's oral treatment (Paxlovid) will be introduced in Korea in
- Company
- Ahn to reduce generic price to counter Lee's hair loss reimb
- by Kim, Jin-Gu Jan 7, 2022 06:06am
- Cheol-Soo Ahn, the presidential candidate of the minor opposition People's Party, pledged to reduce the price of hair loss drug generics. Ahn prosed this as an alternative in concern over the worsening insurance finances that may be caused by Democratic Party Jae-Myung Lee’s mention of reimbursing hair loss treatments On the 5th, Ahn
- Policy
- Is the KRAS gene-targeted drug also released in Korea?
- by Lee, Tak-Sun Jan 6, 2022 06:09am
- The first KRAS gene-targeted anticancer drug approved by the U.S. Food and Drug Administration (FDA) in May last year is expected to be approved soon in Korea. It is Amgen's Lumakras (Sotorasib), which is expected to provide new treatment opportunities to KRAS mutant patients in about 5% to 8% of non-small cell lung cancer patients in Korea.
